Cargando…

Immune Responses Following Locoregional Treatment for Hepatocellular Carcinoma: Possible Roles of Adjuvant Immunotherapy

Hepatocellular carcinoma (HCC) is a common cause of cancer-related deaths worldwide. Unlike other types of cancer, HCC can be treated with locoregional treatments (LRTs) such as radiofrequency ablation (RFA) or transarterial chemoembolization (TACE). However, recurrences following LRTs are common, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Ji-Won, Yoon, Seung-Kew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471821/ https://www.ncbi.nlm.nih.gov/pubmed/34575463 http://dx.doi.org/10.3390/pharmaceutics13091387

Ejemplares similares

Tissue-Resident Lymphocytes: Implications in Immunotherapy for Hepatocellular Carcinoma
por: Han, Ji Won, et al.
Publicado: (2020)

The Immune Modulation Effect of Locoregional Therapies and Its Potential Synergy with Immunotherapy in Hepatocellular Carcinoma
por: Singh, Prabhsimranjot, et al.
Publicado: (2020)

How Biology Guides the Combination of Locoregional Interventional Therapies and Immunotherapy for Hepatocellular Carcinoma: Cytokines and Their Roles
por: Fu, Yan, et al.
Publicado: (2023)

Downstaging of Hepatocellular Carcinoma Prior to Liver Transplant: Is There a Role for Adjuvant Sorafenib in Locoregional Therapy?
por: Vagefi, Parsia A., et al.
Publicado: (2010)

Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy
por: Xue, Jian, et al.
Publicado: (2021)

The Synergistic Effect of Interventional Locoregional Treatments and Immunotherapy for the Treatment of Hepatocellular Carcinoma
por: Brandi, Nicolò, et al.
Publicado: (2023)

The role of adjuvant radiation therapy for locoregionally recurrent papillary thyroid carcinoma
por: Hwang, Hyun, et al.
Publicado: (2021)

Radiological findings in non-surgical recurrent hepatocellular carcinoma: From locoregional treatments to immunotherapy
por: Ippolito, Davide, et al.
Publicado: (2023)

Combination Therapy of Immune Checkpoint Inhibitors with Locoregional Therapy for Hepatocellular Carcinoma
por: Tamai, Yasuyuki, et al.
Publicado: (2023)

Friend or Foe? Locoregional Therapies and Immunotherapies in the Current Hepatocellular Treatment Landscape
por: Young, Shamar, et al.
Publicado: (2023)

Salvage locoregional therapies for recurrent hepatocellular carcinoma
por: Criss, Cody R, et al.
Publicado: (2023)

Recent Advances in Locoregional Therapy of Hepatocellular Carcinoma
por: Podlasek, Anna, et al.
Publicado: (2023)

Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up
por: Lee, Jeong-Hoon, et al.
Publicado: (2018)

Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Clinical Trial
por: Miao, Jingjing, et al.
Publicado: (2022)

Whole blood viscosity is associated with extrahepatic metastases and survival in patients with hepatocellular carcinoma
por: Han, Ji Won, et al.
Publicado: (2021)

Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma
por: Lee, Soon Kyu, et al.
Publicado: (2021)

MRI assessment of hepatocellular carcinoma after locoregional therapy
por: Hussein, Rasha S., et al.
Publicado: (2019)

Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons
por: Makary, Mina S, et al.
Publicado: (2021)

Locoregional therapies for the treatment of locally advanced hepatocellular carcinoma
por: da Motta-Leal-Filho, Joaquim Maurício
Publicado: (2021)

The Biology of Cancer Stem Cells and Its Clinical Implication in Hepatocellular Carcinoma
por: Yoon, Seung Kew
Publicado: (2012)

Cost-effectiveness analysis of metronomic capecitabine as adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma
por: She, Longjiang, et al.
Publicado: (2022)

Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma
por: Yoo, Eun Jin, et al.
Publicado: (2013)

Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions
por: Inchingolo, Riccardo, et al.
Publicado: (2019)

Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
por: Zane, Kylie E., et al.
Publicado: (2021)

Drug-Off Criteria in Patients with Hepatocellular Carcinoma Who Achieved Clinical Complete Response after Combination Immunotherapy Combined with Locoregional Therapy
por: Kudo, Masatoshi
Publicado: (2023)

Role of Exosomes in Immunotherapy of Hepatocellular Carcinoma
por: Tian, Bao-Wen, et al.
Publicado: (2022)

Neoadjuvant immunotherapy of locoregionally advanced solid tumors
por: Tarhini, Ahmad A, et al.
Publicado: (2022)

The Clinical Outcomes and Toxicities of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Plus Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
por: Zou, Rui, et al.
Publicado: (2021)

Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma
por: Park, Dong-Jun, et al.
Publicado: (2021)

Multidisciplinary approach for hepatocellular carcinoma arising from cirrhotic liver with Budd-Chiari syndrome: a case report
por: Kim, Sangmi, et al.
Publicado: (2022)

Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies
por: Makary, Mina S., et al.
Publicado: (2020)

Anti-Glycolytic Drugs in the Treatment of Hepatocellular Carcinoma: Systemic and Locoregional Options
por: Pourbaghi, Miles, et al.
Publicado: (2023)

Factors associated with the survival outcomes of patients with untreated hepatocellular carcinoma: An analysis of nationwide data
por: Kwon, Min Jung, et al.
Publicado: (2023)

Evaluating treatment response following locoregional therapy for hepatocellular carcinoma: A review of the available serological and radiological tools for assessment
por: Cox, Daniel R A, et al.
Publicado: (2023)

Prognostic significance of viable tumor size measurement in hepatocellular carcinomas after preoperative locoregional treatment
por: Hwang, Yoon Jung, et al.
Publicado: (2021)

Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy
por: Francis, David M., et al.
Publicado: (2020)

A platform for locoregional T-cell immunotherapy to control HNSCC recurrence following tumor resection
por: Sharon, Shay, et al.
Publicado: (2021)

Intrahepatic inflammatory IgA(+)PD-L1(high) monocytes in hepatocellular carcinoma development and immunotherapy
por: Sung, Pil Soo, et al.
Publicado: (2022)

Referral and adjuvant treatment patterns after nephrectomy in high‐risk locoregional renal cell carcinoma
por: Dzimitrowicz, Hannah, et al.
Publicado: (2021)

Second Adjuvant Radioiodine Therapy after Reoperation for Locoregionally Persistent or Recurrent Papillary Thyroid Carcinoma
por: Cadena-Piñeros, Enrique, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jvosjdgkaajm002in113n8n1im